Capacitance Electric Fields (CEFs) uses the principles of physics to selectively target and disrupt cancer cells while sparing healthy tissues. Cancer cells are uniquely vulnerable due to their altered membranes, which have distinct electrical and structural properties compared to normal cells. By applying precisely controlled electric fields, CEFs destabilize these membranes, creating tiny, temporary pores that disrupt the cancer cell’s balance of ions and other molecules, ultimately leading to cell death. Unlike traditional treatments like chemotherapy and radiation, which often harm healthy tissues and cause significant side effects, CEF therapy offers a non-invasive and highly targeted solution. Its ability to complement existing therapies—such as enhancing the delivery of chemotherapy drugs or boosting immune responses—positions CEFs as a transformative tool in the fight against cancer, offering patients a more precise and gentle treatment option.

Cancer treatment faces significant challenges due to tumor diversity, therapy resistance, immune system evasion, and toxicity. Conventional methods like chemotherapy, radiation, and immunotherapy are often limited by the tumor’s ability to adapt through genetic mutations and metabolic changes. The tumor microenvironment further complicates treatment by blocking drug penetration, suppressing immunity, and sustaining cancer stem cells, leading to disease progression. To overcome these hurdles, electric field therapies have emerged as a promising alternative, targeting cancer cells differently from traditional approaches. By altering cell voltage, ion transport, and structural integrity, these therapies selectively disrupt cancer growth while sparing healthy tissues. They also improve treatment effectiveness by stabilizing blood vessels, reducing low-oxygen areas, and boosting immune responses. Additionally, electric fields may help prevent metastasis, enhance drug delivery, and improve access to the brain by temporarily opening the blood-brain barrier. As research progresses, combining electric fields with existing treatments could offer a non-invasive, more precise strategy to improve cancer outcomes.

This publication review explores the emerging cancer therapy modality known as Capacitance Electric Field (CEF), a non-invasive approach utilizing low-frequency alternating electric fields to selectively disrupt mitosis in tumor cells while sparing normal tissues. Through preclinical and early clinical studies, CEF has demonstrated tumor growth inhibition via multiple mechanisms including interference with microtubule polymerization, mitotic spindle disruption, and apoptosis induction. The article highlights real-world clinical applications across diverse malignancies such as glioblastoma multiforme, breast cancer, non-small cell lung cancer, and neuroendocrine tumors, documenting improved radiological response, disease control, and in some cases, survival.

Mechanistically, CEF exerts anti-tumor effects by altering cell membrane polarization, perturbing mitotic chromosomal alignment, and modulating immune checkpoints such as PD-L1 and IL-18 expression. Unlike treatments targeting specific mutations, CEF’s biophysical mechanism provides a broad-spectrum therapeutic potential, especially valuable for patients with limited molecular-targeted options. The integration of CEF with conventional therapies, including chemotherapy and radiotherapy, is also discussed, with emphasis on the importance of further randomized controlled trials to validate efficacy, optimize protocols, and expand clinical utility.

The article explores the potential of electric fields as a novel and promising approach in integrated complementary cancer therapy, emphasizing their advantages over conventional therapies, the challenges associated with current cancer treatments, and the need for continued research to optimize the application of electric fields in cancer therapy.​

Electric fields offer a promising avenue for cancer therapy, with multiple mechanisms contributing to their therapeutic effects. By disrupting membrane integrity, interfering with cellular electrical properties, arresting mitosis, enhancing traditional therapies, and modulating the tumor microenvironment, electric fields provide a multifaceted approach to cancer treatment. Ongoing research and clinical trials are essential to fully elucidate these mechanisms and optimize the use of electric fields in oncology.

Brain cancer stands as one of the most formidable and challenging types of cancer to combat. However, a recent breakthrough in research has introduced a novel approach in its treatment utilizing electric fields. This innovative method, termed electro-capacitive cancer therapy (ECCT), presents a non-invasive alternative devoid of the adverse effects commonly associated with traditional treatments like chemotherapy or radiation. ECCT operates by applying an electric field to the tumor region via a specialized helmet. This field disrupts the growth and multiplication of cancerous cells while leaving healthy cells unaffected.

Key Findings

1. Electric Field Distribution in Air Medium: Helmet-1: Average electric field: 1585.72 V/m; highest distribution along the y-axis. Helmet-2: Average electric field: 1413.28 V/m; highest distribution along the x-axis.
2. Electric Field Distribution in Grey Matter and Cancer: Helmet-1: Grey matter: 97.43 V/m; Cancer: 80.58 V/m. Optimal for cancers located on the right and bottom. Helmet-2: Grey matter: 64.20 V/m; Cancer: 52.65 V/m. Optimal for cancers located at the top and bottom.
3. Compensation Error Analysis: Helmet-1 exhibited higher electric field values and a different distribution pattern compared to Helmet-2. The compensation error varied with cancer location, with Helmet-1 showing more significant differences between simulations and experimental data.
4. Field Distribution Patterns: Both sensors effectively measured the electric field distribution, with the 8×8 sensor providing more granular data. The field distribution in the phantom was significantly lower than in the air, highlighting the impact of tissue permittivity.
5. Resolution and Accuracy: The 8×8 sensor achieved an 82.42% reduction in electric field values in the phantom compared to air, while the 3×3 sensor showed a 61.8% reduction. Bilinear interpolation improved the resolution, making the 8×8 sensor preferable for precise measurements.

Clinical Implications

1. Non-Invasive and Precise Measurement: Wire mesh sensors provide a non-invasive method to accurately measure electric fields in therapeutic settings, ensuring proper ECCT application, particularly in sensitive areas like the brain.
2. Voltage Control for Optimized Treatment: Accurate electric field distribution measurement allows for precise control of voltage levels, optimizing therapeutic efficacy and reducing the risk of unintended tissue damage.
3. Effectiveness of Wire Mesh Electrodes: Both active and passive wire mesh electrodes measure electric field distribution accurately without altering the pattern, ensuring reliable dosing and targeted treatment.
4. Enhanced Treatment Planning: Detailed electric field distribution enables fine-tuning of ECCT parameters, maximizing therapeutic benefits and minimizing exposure to healthy tissues.
5. Potential for Broad Clinical Application: The successful use of wire mesh sensors supports their integration into various clinical applications, providing a versatile tool for optimizing electric field-based therapies across different cancer types.

The study introduces a fresh technique for measuring electric fields, potentially upgrading treatment planning for therapies reliant on electric fields. This innovation holds promise in boosting the effectiveness of such treatments for cancer patients. Ultimately, it could revolutionize how we utilize electric fields in cancer treatment, paving the way for significant improvements in patient care.

Key Findings

1. Voltage and Electric Field Distribution: Wire Mesh Sensor 3×3 showed distinct voltage patterns for air and phantom mediums with higher electric field values in air. Wire Mesh Sensor 8×8 provided higher resolution and more detailed electric field distribution, with clear differentiation between air and phantom mediums.
2. Simulation and Experimental Validation: Simulations confirmed significant differences in electric field distribution between air and phantom. Experimental results consistent with simulations, validating the accuracy of wire mesh sensors. The 8×8 sensor demonstrated superior resolution and accuracy compared to the 3×3 sensor.
3. Field Distribution Patterns: Both sensors effectively measured electric field distribution, with the 8×8 sensor providing more granular data. The electric field distribution in the phantom was significantly lower than in air, highlighting the impact of tissue permittivity.
4. Resolution and Accuracy: The 8×8 sensor achieved an 82.42% reduction in electric field values in the phantom compared to air. The 3×3 sensor showed a 61.8% reduction. Bilinear interpolation improved the resolution, making the 8×8 sensor preferable for precise measurements.

Clinical Implications

1. Non-Invasive and Precise Measurement: The wire mesh sensors provide a non-invasive method to accurately measure electric fields in therapeutic settings. This precision ensures that ECCT is applied correctly, particularly in sensitive areas such as the brain, optimizing therapeutic outcomes and minimizing side effects.
2. Voltage Control for Optimized Treatment: The findings emphasize the importance of voltage control in ECCT. Ensuring stable and appropriate voltage levels can optimize therapeutic efficacy, effectively inhibiting cancer cell growth while reducing the risk of unintended tissue damage.
3. Effectiveness of Wire Mesh Electrodes: Both active and passive wire mesh electrodes accurately measure electric field distribution without altering the pattern. This reliability is crucial for ensuring accurate dosing and targeted treatment, which is essential for effective cancer therapy.
4. Enhanced Treatment Planning: Understanding the electric field distribution within the body model allows for fine-tuning ECCT parameters. This knowledge enables clinicians to maximize therapeutic benefits by targeting cancer cells more effectively and minimizing exposure to healthy tissues.
5. Potential for Broad Clinical Application: The successful use of wire mesh sensors to analyze electric field distribution supports their integration into broader clinical applications. This technology can be used in various cancer treatments beyond brain cancer, providing a versatile tool for optimizing electric field-based therapies across different cancer types.

Researchers have explored a pioneering approach to cancer treatment involving continuous, one-directional electric fields. These steady electric fields exert pressures on tumor cells, either propelling or retracting them. Using a computer model, scientists measured the electric force acting on tumor cells within breast cancer tissue. They evaluated two scenarios: one with a uniform distribution of the electric field across the tissue and another concentrating more powerfully on the tumor cells. Results highlighted a significantly higher electric force on the tumor cells compared to normal cells, further intensifying when the electric field specifically targeted the tumor cells. These findings led researchers to suggest that electric fields could potentially eliminate tumor cells by inducing their rupture or bursting.

Key Findings

1. Non-Homogeneous EF Intensity at Lesion Boundary: The electric field (EF) intensity was non-homogeneous at the boundary between the lesion and the medium, but homogeneous within the lesion itself. This non-homogeneity at the boundary is crucial for the effectiveness of ECCT, as it suggests targeted treatment at the tumor edges where cancer cells are more likely to detach and die.
2. Dependence on Dielectric Constant: The EF intensity increased with higher dielectric constants of the medium. This indicates that the medium’s properties significantly influence the treatment efficacy, with tumor tissues—typically having higher dielectric constants than normal tissues—being more susceptible to the effects of ECCT.
3. Voltage Variation and EF Gradient: Increasing the applied voltage difference (Vpp) led to a higher gradient of EF intensity, enhancing the therapeutic potential of ECCT. Higher applied voltages resulted in steeper EF gradients, which can be used to optimize treatment parameters.
4. Strong Dielectrophoretic Force (FDEP) at Lesion Boundary: A strong dielectrophoretic force was observed at the lesion-medium boundary, contributing to the detachment of the tumor mass from surrounding tissues. This force is crucial for disrupting microtubule polymerization, causing mitotic arrest and subsequent cell death.
5. Impact on Different Lesion Sizes: Variations in lesion diameter did not significantly affect the EF intensity distribution, suggesting that ECCT’s effectiveness is consistent across different tumor sizes. This versatility is beneficial for treating a wide range of cancer cases.
6. Relevance to Tubulin Dimer Size: The dielectrophoretic force was more related to the tubulin dimer size rather than the lesion size, indicating that even small changes in EF can significantly impact cell mitosis. This highlights the impact of EF on cellular structures, preventing cancer cells from completing mitosis and leading to cell cycle arrest and death.

Clinical Implications

1. Non-Invasive and Targeted Therapy: ECCT’s ability to generate strong electric forces specifically at the tumor boundary without affecting surrounding tissues underscores its potential as a targeted, non-invasive cancer therapy. This method reduces the need for aggressive surgical interventions.
2. Consistency Across Tumor Sizes: The effectiveness of ECCT across different lesion sizes suggests it could be widely applicable in clinical settings, providing a versatile treatment option for various cancer types and stages.
3. Potential for Combination Therapy: ECCT could be integrated with other treatments, such as chemotherapy, to enhance overall efficacy. Its non-invasive nature and targeted action could help reduce side effects and improve patient outcomes.

The paper presents electric fields as a novel and effective treatment for blood cancer, a serious condition arising from the abnormal growth of white blood cells. The authors highlighted the impact of various factors—electrode size, shape, material, and voltage—on the electric field distribution in blood. Their suggestion is to use electrodes with high voltage and small size, generating robust electric fields capable of eliminating cancer cells through dielectrophoresis or electrochemical processes. This method holds promise as a potentially safer and more cost-effective alternative to other treatments.

Key Findings

1. Optimal Electrode Arrangement: Model 3, where electrodes are placed on two sides of the object with opposite electric poles, provided the most uniform and effective electric field distribution. This configuration is crucial for ensuring that the electric field can effectively target cancer cells throughout the treatment area.
2. Electric Field Distribution in Different Mediums: In simulations conducted in both air and blood mediums, Model 3 consistently showed superior electric field distribution compared to other configurations. This uniformity is essential for maximizing the therapeutic effects of ECCT.
3. Effect of Voltage on Electric Field Intensity: Increasing the input voltage directly increased the electric field intensity. At 0.34 V input voltage, the maximum electric field values for normal blood, B lymphocytes, and T lymphocytes were 22.6 V/m, 22.85 V/m, and 24.88 V/m, respectively. Doubling the input voltage to 0.68 V further increased these values, demonstrating that higher electric field intensities can be achieved to enhance therapeutic effects.
4. Dielectrophoretic Migration: Leukocytes were observed to migrate towards regions with higher electric fields, indicating positive dielectrophoresis. This migration is crucial for concentrating the therapeutic effects of ECCT on cancer cells.
5. Voltage Threshold for Leukocyte Breakdown: A minimum voltage of 0.34 V was identified as necessary to convert leukocytes into electric current, facilitating their breakdown. This threshold voltage is critical for ensuring effective disruption of cancer cells.
6. Impact of Photosensitizers: Adding a photosensitizer like Porphyrin can lower the permittivity of blood, enhancing the dielectrophoretic effects and increasing leukocyte breakdown. This approach could further improve the efficacy of ECCT in clinical settings.
7. Non-Invasive Treatment Potential: ECCT offers a non-invasive method to target blood cancer cells, potentially reducing the need for aggressive treatments like chemotherapy and radiotherapy. This highlights the potential of ECCT as a safer and more comfortable treatment option for patients.
8. Safety and Efficacy: The study demonstrates that ECCT effectively targets cancer cells without significantly impacting healthy cells, supporting its safety as a treatment modality.

Advancements in medical technology are opening up new possibilities for cancer treatment. Specifically, the use of external electric fields has shown potential in inhibiting cancer growth. Devices such as Tumor Treating Fields (TTFields), nanosecond Pulsed Electric Fields (nsPEF), picosecond Pulsed Electric Fields (psPEF), and Electro-Capacitive Cancer Therapy (ECCT) are being studied and developed for this purpose. Among these, ECCT has been particularly effective and is being closely investigated, especially in breast cancer treatment.

The study contributes to enhancing ECCT systems by incorporating Integrated Circuit technology. This integration has the potential to significantly enhance the efficiency and effectiveness of the system in treating cancer.